Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Pediatrics
Erschienen in: World Journal of Pediatrics 2/2021

03.03.2021 | Review Article

Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin

verfasst von: Jing Chen, Xiao-Hui Qiao, Jian-Hua Mao

Erschienen in: World Journal of Pediatrics | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Idiopathic nephrotic syndrome is a common form of glomerular nephropathy in children, with an incidence rate of 1.15–16.9/100,000 depending on different nationalities and ethnicities. The etiological factors and mechanisms of childhood idiopathic nephrotic syndrome have not yet been fully elucidated. This review summarizes the progress of the immunopathogenesis of idiopathic nephrotic syndrome in children.

Data sources

We review the literature on the immunopathogenesis of idiopathic nephrotic syndrome in children. Databases including Medline, Scopus, and Web of Science were searched for studies published in any language with the terms “children”, “idiopathic nephrotic syndrome”, “immunopathogenesis”, “T cells”, “circulating permeability factors”, and “B cells”.

Results

Dysfunction in T lymphocytes and pathogenic circulatory factors were indicated to play key roles in the pathogenesis of idiopathic nephrotic syndrome. Recently, some studies have shown that cellular immune dysfunction may also be involved in the pathogenesis of idiopathic nephrotic syndrome.

Conclusions

Both T- and B-cell dysfunction may play significant roles in the pathogenesis of idiopathic nephrotic syndrome, like two sides of one coin, but the role of B cell seems more important than T cells.
Literatur
1.
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int. 2012;82:840–56.PubMedCrossRef
2.
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392:61–74.PubMedCrossRef
3.
Roth KS, Amaker BH, Chan JC. Nephrotic syndrome: pathogenesis and management. Pediatr Rev. 2002;23:237–48.PubMedCrossRef
4.
Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013;62:403–41.PubMedCrossRef
5.
Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol. 2006;21:344–9.PubMedCrossRef
6.
Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol. 2001;16:658–61.PubMedCrossRef
7.
Paik KH, Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, et al. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol. 2007;22:389–95.PubMedCrossRef
8.
Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, Bodria M, Ozaltin F, Emma F, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol. 2017;28:3055–65.PubMedPubMedCentralCrossRef
9.
Davin JC. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol. 2016;31:207–15.PubMedCrossRef
10.
Daniel V, Trautmann Y, Konrad M, Nayir A, Scharer K. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol. 1997;47:289–97.PubMed
11.
Kaneko K, Tsuji S, Kimata T, Kitao T, Yamanouchi S, Kato S. Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T cells to podocytes. World J Pediatr. 2015;11:21–8.PubMedCrossRef
12.
Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167–73.PubMedCrossRef
13.
Lin CY, Hsu HC. Histopathological and immunological studies in spontaneous remission of nephrotic syndrome after intercurrent measles infection. Nephron. 1986;42:110–5.PubMedCrossRef
14.
15.
Federico A, Merletti MG, Lisi E, De Finis F, Trivelli G, Sopranzi F. Nephrotic syndrome as first presentation of malignant thymoma: description of a clinical case. G Ital Nefrol. 2010;27:674–9.PubMed
16.
Geylis M, Rosen GB, Danino D, Schreiber R, Hassan D, Nalbandyan K, et al. Hodgkin’s lymphoma, nephrotic syndrome, and echinococcosis cysts: an unusual association and literature review. Pediatr Hematol Oncol. 2019;36:40–5.PubMedCrossRef
17.
Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113:1390–7.PubMedPubMedCentralCrossRef
18.
Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH. Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol. 2014;29:2333–40.PubMedPubMedCentralCrossRef
19.
Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2009;20:260–6.PubMedPubMedCentralCrossRef
20.
Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, et al. Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol. 2015;30:309–16.PubMedCrossRef
21.
Ahmed HM, Ezzat DA, Doudar NA, Adel M. Urinary CD80 as a replacement for renal biopsy for diagnosis of pediatric minimal change disease. Iran J Kidney Dis. 2018;12:107–11.PubMed
22.
Tsuji S, Kimata T, Yamanouchi S, Kitao T, Kino J, Suruda C, et al. Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome. Pediatr Int. 2017;59:643–6.PubMedCrossRef
23.
Zhao B, Han H, Zhen J, Yang X, Shang J, Xu L, et al. CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study. PeerJ. 2018;6:e5400.PubMedPubMedCentralCrossRef
24.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369:2416–23.PubMedPubMedCentralCrossRef
25.
Benigni A, Gagliardini E, Remuzzi G. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370:1261–3.PubMedCrossRef
26.
Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370:1263–4.PubMed
27.
Kaneko K, Tsuji S, Kimata T. Role of gut microbiota in idiopathic nephrotic syndrome in children. Med Hypotheses. 2017;108:35–7.PubMedCrossRef
28.
Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet. 1972;2:343–8.PubMedCrossRef
29.
McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:2115–21.PubMedCrossRef
30.
Ali AA, Wilson E, Moorhead JF, Amlot P, Abdulla A, Fernando ON, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation. 1994;58:849–52.PubMedCrossRef
31.
Le Berre L, Godfrin Y, Gunther E, Buzelin F, Perretto S, Smit H, et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. J Clin Invest. 2002;109:491–8.PubMedPubMedCentralCrossRef
32.
Haffner K, Zimmerhackl LB, von Schnakenburg C, Brandis M, Pohl M. Complete remission of post-transplant FSGS recurrence by long-term plasmapheresis. Pediatr Nephrol. 2005;20:994–7.PubMedCrossRef
33.
Kemper MJ, Wolf G, Muller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med. 2001;344:386–7.PubMedCrossRef
34.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171–354.PubMedCrossRef
35.
Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 2016;17:104.PubMedPubMedCentralCrossRef
36.
Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW. Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol. 1999;10:1700–8.PubMedCrossRef
37.
Lennon R, Singh A, Welsh GI, Coward RJ, Satchell S, Ni L, et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol. 2008;19:2140–9.PubMedPubMedCentralCrossRef
38.
Bakker WW, van Dael CM, Pierik LJ, van Wijk JA, Nauta J, Borghuis T, et al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol. 2005;20:1410–5.PubMedCrossRef
39.
Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, et al. Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res. 2015;2015:714964.PubMedPubMedCentralCrossRef
40.
Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55–63.PubMedCrossRef
41.
Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, et al. Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol. 2015;30:301–7.PubMedCrossRef
42.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952–60.PubMedPubMedCentralCrossRef
43.
Kronbichler A, Saleem MA, Meijers B, Shin JI. Soluble urokinase receptors in focal segmental glomerulosclerosis: a review on the scientific point of view. J Immunol Res. 2016;2016:2068691.PubMedPubMedCentralCrossRef
44.
Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85:636–40.PubMedCrossRef
45.
Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85:649–58.PubMedCrossRef
46.
Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem. 2004;279:34827–32.PubMedCrossRef
47.
Keisuke S, Kohei M, Takuji E, Tomoki M, Yuichi M, Rina O, et al. Role of cathepsin L in idiopathic nephrotic syndrome in children. Med Hypotheses. 2020;141:109718.PubMedCrossRef
48.
Chugh SS, Clement LC, Mace C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis. 2012;59:284–92.PubMedCrossRef
49.
Clement LC, Avila-Casado C, Mace C, Soria E, Bakker WW, Kersten S, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 2011;17:117–22.PubMedCrossRef
50.
Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med. 2014;20:37–46.PubMedCrossRef
51.
Cara-Fuentes G, Segarra A, Silva-Sanchez C, Wang H, Lanaspa MA, Johnson RJ, et al. Angiopoietin-like-4 and minimal change disease. PLoS ONE. 2017;12:e0176198.PubMedPubMedCentralCrossRef
52.
Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22:2098–105.PubMedPubMedCentralCrossRef
53.
Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D’Agati VD, et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol. 2015;26:1443–8.PubMedPubMedCentralCrossRef
54.
Clark AJ, Jabs K, Hunley TE, Jones DP, VanDeVoorde RG, Anderson C, et al. Urinary apolipoprotein AI in children with kidney disease. Pediatr Nephrol. 2019;34:2351–60.PubMedPubMedCentralCrossRef
55.
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.PubMedPubMedCentralCrossRef
56.
Ahmad A, Mitrofanova A, Bielawski J, Yang Y, Marples B, Fornoni A, et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes. FASEB J. 2017;31:771–80.PubMedCrossRef
57.
LaConte L, Mukherjee K. Structural constraints and functional divergences in CASK evolution. Biochem Soc Trans. 2013;41:1017–22.PubMedCrossRef
58.
Lehtonen S, Lehtonen E, Kudlicka K, Holthofer H, Farquhar MG. Nephrin forms a complex with adherens junction proteins and CASK in podocytes and in Madin-Darby canine kidney cells expressing nephrin. Am J Pathol. 2004;165:923–36.PubMedPubMedCentralCrossRef
59.
Caruana G. Genetic studies define MAGUK proteins as regulators of epithelial cell polarity. Int J Dev Biol. 2002;46:511–8.PubMed
60.
Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom. 2005;4:1920–32.CrossRef
61.
Beaudreuil S, Zhang X, Herr F, Harper F, Candelier JJ, Fan Y, et al. Circulating CASK is associated with recurrent focal segmental glomerulosclerosis after transplantation. PLoS ONE. 2019;14:e0219353.PubMedPubMedCentralCrossRef
62.
Ling C, Wang X, Chen Z, Fan J, Meng Q, Zhou N, et al. Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome. Front Pediatr. 2019;7:377.PubMedPubMedCentralCrossRef
63.
Printza N, Papachristou F, Tzimouli V, Taparkou A, Kanakoudi-Tsakalidou F. Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome. NDT Plus. 2009;2:435–6.PubMedPubMedCentral
64.
Hsiao CC, Tu KH, Hsieh CY, Lee CC, Chang CH, Fan PC, et al. Immunoglobulin E and G levels in predicting minimal change disease before renal biopsy. Biomed Res Int. 2018;2018:3480309.PubMedPubMedCentralCrossRef
65.
Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, et al. Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int. 2006;69:2251–60.PubMedCrossRef
66.
Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2–9.PubMedCrossRef
67.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.PubMedCrossRef
68.
Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172:757–64.PubMedPubMedCentralCrossRef
69.
Ravani P, Bonanni A, Ghiggeri GM. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017;7:e013319.PubMedPubMedCentralCrossRef
70.
Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370:1268–70.PubMedCrossRef
71.
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.PubMedPubMedCentralCrossRef
72.
Ahmad SB, Appel GB. Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int. 2020;97:29–31.PubMedCrossRef
73.
De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421–30.PubMedCrossRef
74.
Godel M, Grahammer F, Huber TB. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2015;372:1073.PubMedCrossRef
75.
Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97:163–74.PubMedCrossRef
76.
van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96:1292–302.PubMedCrossRef
Metadaten
Titel
Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin
verfasst von
Jing Chen
Xiao-Hui Qiao
Jian-Hua Mao
Publikationsdatum
03.03.2021
Verlag
Springer Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 2/2021
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-020-00400-1

Weitere Artikel der Ausgabe 2/2021

World Journal of Pediatrics 2/2021 Zur Ausgabe

Meta-analysis

Multisystem inflammatory syndrome in pediatric COVID-19 patients: a meta-analysis

Personal Viewpoint

Pediatric food allergy clinic: a way to improve the quality of service

Letter to Editor

Prevalence and characteristics of Kawasaki disease before and during the COVID-19 pandemic

Review Article

Reducing neonatal mortality and respiratory distress syndrome associated with preterm birth: a scoping review on the impact of antenatal corticosteroids in low- and middle-income countries

Original Article

Continuous positive airway pressure acutely increases exercise duration in children with severe therapy-resistant asthma: a randomized crossover trial

Personal Viewpoint

Sleep in children with eosinophilic esophagitis

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise